This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-02. Anything still debated is marked as such rather than presented as settled.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical form for research-grade material |
| Solubility | Soluble in water | Aqueous buffer also used |
| Typical storage | -20 degrees Celsius or below | Desiccated and protected from light |
| Primary analytical method | RP-HPLC with UV detection | Purity expressed as relative peak area |
| Identity confirmation | ESI-MS or LC-MS | Compared with calculated 711.85 Da |
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
== History == The FDA approved cipaglucosidase alfa in combination with miglustat based on evidence from a clinical trial (Trial 1/NCT03729362) of 123 participants with late-onset Pompe disease. Safety data from the use of cipaglucosidase alfa in combination with miglustat was primarily obtained from one clinical trial (Trial 1, NCT03729362). Data from two other trials (Trial 2/NCT02675465 and Trial 3/NCT04138277) were also reviewed for completeness of the safety assessment. The three trials enrolled 151 participants with late-onset Pompe disease. The trials were conducted at 61 sites in 24 countries around the world, including the United States. In Trial 1, 123 adults with late-onset Pompe disease received either cipaglucosidase alfa intravenously once every two weeks for 52 weeks in combination with miglustat, or another medication (called the active comparator) intravenously once every two weeks for 52 weeks in combination with placebo. Of the 123 participants, 95 previously received enzyme replacement therapy, and 28 never received enzyme replacement therapy before the trial. Neither the participants nor the healthcare providers knew which treatment was being given until after Week 52.
== Further reading == Barta J. Fruit Drying Principles (Chapter 5) In: Handbook of Fruits and Fruit Processing Hui YH. Ed. Blackwell Publishing, Iowa (2006) Ratti C. and Mujumdar A. S. Drying of Fruit (Chapter 7) In: Processing Fruit Barrett D. M., Somogyi L. and Ramaswamy H., Eds. CRC Press, New York (2005)
Recent genomic and phylogenomic approaches have significantly clarified plastid genome evolution, the horizontal movement of endosymbiont genes to the "host" nuclear genome, and plastid spread throughout the eukaryotic tree of life. It is accepted that both euglenophytes and chlorarachniophytes obtained their chloroplasts from chlorophytes that became endosymbionts. In particular, euglenophyte chloroplasts share the most resemblance with the genus Pyramimonas. However, there is still no clear order in which the secondary and tertiary endosymbioses occurred for the "chromist" lineages (ochrophytes, cryptophytes, haptophytes and myzozoans). Two main models have been proposed to explain the order, both of which agree that cryptophytes obtained their chloroplasts from red algae. One model, hypothesized in 2014 by John W. Stiller and coauthors, suggests that a cryptophyte became the plastid of ochrophytes, which in turn became the plastid of myzozoans and haptophytes. The other model, suggested by Andrzej Bodył and coauthors in 2009, describes that a cryptophyte became the plastid of both haptophytes and ochrophytes, and it is a haptophyte that became the plastid of myzozoans instead. In 2024, a third model by Filip Pietluch and coauthors proposed that there were two independent endosymbioses with red algae: one that originated the cryptophyte plastids (as in the previous models), and subsequently the haptophyte plastids; and another that originated the ochrophyte plastids, where the myzozoans obtained theirs.
== Standards == ISO 676:1995 – contains the information about the nomenclature of the variety and cultivars ISO 5563:1984 – a specification for its dried leaves of Mentha piperita Linnaeus Peppermint oil – ISO 856:2006
Sources: en.wikipedia.org
== Metal recovery == Metal recovery is the final step in a hydrometallurgical process, in which metals suitable for sale as raw materials are produced. Sometimes, however, further refining is needed to produce ultra-high purity metals. The main types of metal recovery processes are electrolysis, gaseous reduction, and precipitation. For example, a major target of hydrometallurgy is copper, which is conveniently obtained by electrolysis. Cu2+ ions are reduced to Cu metal at low potentials, leaving behind contaminating metal ions such as Fe2+ and Zn2+.
==== Anti-Jo-1 ==== Although anti-Jo-1 antibodies are often included with ANAs, they are actually antibodies to the cytoplasmic protein, Histidyl-tRNA synthetase – an aminoacyl-tRNA synthetase essential for the synthesis of histidine loaded tRNA. They are highly associated with polymyositis and dermatomyositis, and are rarely found in other connective tissue diseases. Around 20–40% of polymyositis is positive for Jo-1 antibodies and most will have interstitial lung disease, HLA-DR3 and HLA-DRw52 human leukocyte antigen (HLA) markers; collectively known as Jo-1 syndrome.
Tourism is the third-largest contributor to Malaysia's GDP, after the manufacturing and commodities sectors. In 2019, the sector contributed about 15.9% to the total GDP. According to the World Tourism Organization, Malaysia was the fourteenth-most visited country in the world, and the fourth-most visited country in Asia in 2019, with over 26.1 million visits. Malaysia was ranked 38th in the Travel and Tourism Competitiveness Report 2019. Its international tourism receipts in 2019 amounted to $19.8 billion. The country has developed into a centre of Islamic banking and has the highest number of female workers in that industry. Knowledge-based services are also expanding. In 2020, Malaysia exported high-tech products worth $92.1 billion, the second-highest in ASEAN, after Singapore. Malaysia was ranked 34th in the Global Innovation Index in 2025, and 32nd in the Global Competitiveness Report in 2022.
Sources: en.wikipedia.org
==== Illicit drugs ==== The sources and production mechanisms of illegal drugs has been another area that has seen successful application of hydrogen isotope characterization. Usually, as with other applications of stable isotope techniques, results are best when data for multiple stable isotopes are compared with one another. δ2H, δ13C and δ15N have been used together to analyze tablets of MDA and MDMA and has successfully identified differences which could be used to differentiate between different sources or production mechanisms. The same combination of stable isotopes with the addition of δ18O was applied to heroin and associated packaging and could successfully distinguish between different samples. Analysis using deuterium NMR was also able to shed light on the origin and processing of both cocaine and heroin. In the case of heroin this site-specific natural isotopic fraction measured by deuterium NMR (SNIF-NMR) method could be used for determining the geographic origin of the molecule by analyzing so-called natural sites (which were present in the morphine from which heroin is made), as well as gaining information on the synthesis process by analyzing the artificial sites (added during drug processing).
When the PSOE took office the Spanish economy was in full expansion. One of the factors that had made this possible was the arrival of several million emigrants from Latin America, the Maghreb and Eastern Europe. But part of them were "undocumented" migrants so the government decided to proceed with a massive "regularization" throughout 2005 that affected about 700 000 people who obtained a residence permit by presenting a contract of employment. The PP accused the government of provoking a "call effect" of new emigrants. The integration of the four million emigrants who had arrived in Spain in the last 10 years – so that foreigners now accounted for almost 10% of the population – posed an enormous challenge for Spanish society. The main "engine" of economic growth was being the construction sector, driven by increased demand. However, much of it was the result of a speculative movement around the "brick" as many people did not buy the homes to inhabit them but to place their savings hoping to sell them later at a higher price. This was how the "Spanish property bubble" was fed. But in the summer of 2007, the outbreak of the subprime mortgage crisis in the United States had an immediate repercussion in Europe and especially in Spain, where housing prices stopped rising, the construction sector came to a standstill and this dragged down the economy as a whole which began to grow at a slower pace with the consequent increase in unemployment.
==== Additional functions ==== Aside from the key functions of sample management, instrument and application integration, and electronic data exchange, there are numerous additional operations that can be managed in a LIMS. This includes but is not limited to:
== History == Dextromoramide was discovered and patented in 1956 by Paul Janssen at Janssen Pharmaceuticals, who also discovered fentanyl, another important synthetic opioid, widely used to treat pain and in combination with other drugs as an anaesthetic, as well as haloperidol, piritramide, the loperamide-diphenoxylate series and other important drugs. Dextromoramide was much favoured by drug users in Australia in the 1970s and the United Kingdom. It has the main proprietary name of Palfium amongst others, though as of mid-2004 the drug was discontinued in the UK due to limited supplies of precursor chemicals. Although this is true, it is believed there was an approximate one year shortage of Dextromoramide and the real reason that Palfium was not put back into production for the UK market is because of how addictive and potent it is as an oral painkiller. Dependence liability is similar to morphine, but with a less severe withdrawal syndrome. The only European countries that now use the brand Palfium are the Netherlands, Ireland and Luxembourg. It is presumably able to be imported into other Schengen zone countries under Title 76 of said treaty coming into force in 2002. It is a Schedule I Narcotic controlled substance in the United States, with a DEA ACSCN of 9613 and an annual aggregate manufacturing quota of zero as of 2013, and had been out of use in the United States for around a decade when the new Controlled Substances Act 1970 was promulgated. The salts of dextromoramide in use are the hydrochloride (free base conversion ratio 0.915) and tartrate (0.724).
Sources: en.wikipedia.org
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.
Once dissolved, the peptide is exposed to hydrolysis, oxidation, and aggregation pathways that are slowed in the dry state. Freeze-thaw cycling and warm storage accelerate these losses. Keeping the lyophilized powder cold and dry is the usual way to limit degradation.
No single pharmacopeial monograph covers ipamorelin, so suppliers apply their own specifications. Certificates of analysis therefore differ in the tests performed and the limits set. Independent laboratory verification is often needed to compare materials from different sources.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.